Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237609542> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4237609542 endingPage "e21158" @default.
- W4237609542 startingPage "e21158" @default.
- W4237609542 abstract "e21158 Background: In murine cancer models, the two IFN-γ inducible chemokines CXCL9 and CXCL10, those bind to the common receptor CXCR3, recruit NK cells and tumor-suppressive lymphocytes into the tumor site and impair tumor growth and metastatic spread. In human breast cancer, we and others have shown that high levels of CXCL9 mRNA correlate with favorable prognosis and the number of infiltrating lymphocytes. Raising the intratumoral level of CXCR3 ligands might therefore be a feasible way to enhance the infiltration by tumor-suppressive immune cells and to improve immune intervention in breast cancer. Inhibition of cyclooxygenases (COX) has been shown to inhibit tumor growth and metastases formation in a lymphocytic and IFN-γ dependent manner. We therefore tested whether COX inhibition induces CXCR3 ligand secretion from breast cancer cells. Methods: Human MCF7 and MDAMB 231 breast cancer cells were stimulated with IFNγ with or without prostaglandin E2 (PGE2) or COX inhibitors (indomethacin, aspirin, celecoxib). CXCL9 and CXCL10 release was measured by ELISA. COX-1 and COX-2 expression was measured in 45 breast cancer samples and correlated with intratumoral CXCR3 ligand concentration. Results: PGE2 inhibits CXCL10 and CXCL9 release from breast cancer cells. Aspirin and indomethacin enhance the INF-γ mediated secretion of these CXCR3 ligands by inhibition of endogenous cyclooxygenases. Celecoxib has this effect only at low concentrations, at higher concentrations is shows PGE2 agonistic effects. In human breast cancer samples, COX-2 overexpression inversely correlates with CXCR3 ligand concentration, which shows that the mechanism of PGE2 induced CXCL9/CXCL10 suppression might also be relevant in vivo. Conclusions: Suppressing endogenous PGE2 by cyclooxygenase inhibition increases CXCL9 and CXCL10 release from breast cancer cells and is therefore a feasible way to enhance the infiltration of breast tumors by tumor-suppressive lymphocytes. However, our results show that unselective COX inhibitors might be more suitable than the COX-2 specific celecoxib. Clinical trials are now warranted to clarify the mechanisms and therapeutic efficacy of COX inhibition in breast cancer." @default.
- W4237609542 created "2022-05-12" @default.
- W4237609542 creator A5024873809 @default.
- W4237609542 creator A5026807639 @default.
- W4237609542 creator A5045660631 @default.
- W4237609542 creator A5051982560 @default.
- W4237609542 creator A5062629229 @default.
- W4237609542 creator A5066655656 @default.
- W4237609542 creator A5079186386 @default.
- W4237609542 date "2011-05-20" @default.
- W4237609542 modified "2023-09-25" @default.
- W4237609542 title "The effects of cyclooxygenase inhibition on CXCR3 ligand secretion in breast cancer." @default.
- W4237609542 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e21158" @default.
- W4237609542 hasPublicationYear "2011" @default.
- W4237609542 type Work @default.
- W4237609542 citedByCount "0" @default.
- W4237609542 crossrefType "journal-article" @default.
- W4237609542 hasAuthorship W4237609542A5024873809 @default.
- W4237609542 hasAuthorship W4237609542A5026807639 @default.
- W4237609542 hasAuthorship W4237609542A5045660631 @default.
- W4237609542 hasAuthorship W4237609542A5051982560 @default.
- W4237609542 hasAuthorship W4237609542A5062629229 @default.
- W4237609542 hasAuthorship W4237609542A5066655656 @default.
- W4237609542 hasAuthorship W4237609542A5079186386 @default.
- W4237609542 hasConcept C121608353 @default.
- W4237609542 hasConcept C126322002 @default.
- W4237609542 hasConcept C12823836 @default.
- W4237609542 hasConcept C13373296 @default.
- W4237609542 hasConcept C17502307 @default.
- W4237609542 hasConcept C203014093 @default.
- W4237609542 hasConcept C25532541 @default.
- W4237609542 hasConcept C2776107976 @default.
- W4237609542 hasConcept C502942594 @default.
- W4237609542 hasConcept C530470458 @default.
- W4237609542 hasConcept C5858377 @default.
- W4237609542 hasConcept C71924100 @default.
- W4237609542 hasConcept C8891405 @default.
- W4237609542 hasConcept C96232424 @default.
- W4237609542 hasConcept C98274493 @default.
- W4237609542 hasConceptScore W4237609542C121608353 @default.
- W4237609542 hasConceptScore W4237609542C126322002 @default.
- W4237609542 hasConceptScore W4237609542C12823836 @default.
- W4237609542 hasConceptScore W4237609542C13373296 @default.
- W4237609542 hasConceptScore W4237609542C17502307 @default.
- W4237609542 hasConceptScore W4237609542C203014093 @default.
- W4237609542 hasConceptScore W4237609542C25532541 @default.
- W4237609542 hasConceptScore W4237609542C2776107976 @default.
- W4237609542 hasConceptScore W4237609542C502942594 @default.
- W4237609542 hasConceptScore W4237609542C530470458 @default.
- W4237609542 hasConceptScore W4237609542C5858377 @default.
- W4237609542 hasConceptScore W4237609542C71924100 @default.
- W4237609542 hasConceptScore W4237609542C8891405 @default.
- W4237609542 hasConceptScore W4237609542C96232424 @default.
- W4237609542 hasConceptScore W4237609542C98274493 @default.
- W4237609542 hasIssue "15_suppl" @default.
- W4237609542 hasLocation W42376095421 @default.
- W4237609542 hasOpenAccess W4237609542 @default.
- W4237609542 hasPrimaryLocation W42376095421 @default.
- W4237609542 hasRelatedWork W1977122901 @default.
- W4237609542 hasRelatedWork W2068868975 @default.
- W4237609542 hasRelatedWork W2109220360 @default.
- W4237609542 hasRelatedWork W2342284301 @default.
- W4237609542 hasRelatedWork W2765724200 @default.
- W4237609542 hasRelatedWork W2772015973 @default.
- W4237609542 hasRelatedWork W2793584160 @default.
- W4237609542 hasRelatedWork W2952016598 @default.
- W4237609542 hasRelatedWork W2978209634 @default.
- W4237609542 hasRelatedWork W4224210543 @default.
- W4237609542 hasVolume "29" @default.
- W4237609542 isParatext "false" @default.
- W4237609542 isRetracted "false" @default.
- W4237609542 workType "article" @default.